| Seronegative coeliac disease: clearing the diagnostic dilemma |
17 |
| Vitamin D in inflammatory bowel disease: more than just a supplement |
16 |
| Advances in the treatment of gastric cancer |
16 |
| Probiotics for prevention of Clostridium difficile infection |
14 |
| The evolution of antimicrobial resistance in Salmonella Typhi |
14 |
| The emerging role of immunotherapy for esophageal cancer |
10 |
| Incidence of gallstone disease and complications |
10 |
| An update on the pathogenesis of cholesterol gallstone disease |
9 |
| Mouse models of gallstone disease |
9 |
| Diagnosis and treatment of pancreatic exocrine insufficiency |
9 |
| Total pancreatectomy and islet autotransplantion for chronic and recurrent acute pancreatitis |
9 |
| On cell death in the intestinal epithelium and its impact on gut homeostasis |
9 |
| NSAIDs and the small bowel |
9 |
| Modifier genes in cystic fibrosis-related liver disease |
8 |
| Management of pancreatic exocrine insufficiency |
7 |
| Obeticholic acid in primary biliary cholangitis: where we stand |
7 |
| Guilt by association: intestinal metaplasia does not progress to gastric cancer |
7 |
| The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease |
7 |
| New cross-sectional imaging in IBD |
6 |
| Esophageal dilation in eosinophilic esophagitis: risks, benefits, and when to do it |
6 |
| Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment |
6 |
| Gastroduodenal motility disorders |
6 |
| Helicobacter pylori resistance to current therapies |
6 |
| Chronic pancreatitis: an update on genetic risk factors |
6 |
| Management of acute pancreatitis in the first 72 hours |
6 |
| Pharmacologic management and prevention of acute pancreatitis |
5 |
| Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship |
5 |
| Myths and realities about alcohol and smoking in chronic pancreatitis |
5 |
| Proton pump inhibitors and risk of Clostridium difficile infection: association or causation? |
5 |
| Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways |
5 |
| Advances in the treatment of gastric cancer: 2019 |
5 |
| Hemorrhoids: what are the options in 2018? |
4 |
| Effects of bariatric surgery on the esophagus |
4 |
| Diagnosis: gastric intestinal metaplasia - what to do next? |
4 |
| Genetics in biliary atresia |
4 |
| Genetics of polycystic liver diseases |
4 |
| Genetics of gallstone disease revisited: updated inventory of human lithogenic genes |
4 |
| Macrophage interactions with fungi and bacteria in inflammatory bowel disease |
4 |
| Adverse effects of proton pump inhibitors: fact or fake news? |
4 |
| The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil |
4 |
| New paradigms for organ allocation and distribution in liver transplantation |
4 |
| Liver disease in patients with cystic fibrosis |
4 |
| How to use Rome IV criteria in the evaluation of esophageal disorders |
4 |
| Potential of multiomics technology in precision medicine |
4 |
| The dark side of the colon: current issues surrounding the significance, prevalence, detection, diagnosis and management of serrated polyps |
4 |
| The overlap of irritable bowel syndrome and noncoeliac gluten sensitivity |
4 |
| Excluding irritable bowel syndrome in the inflammatory bowel disease patient: how far to go? |
4 |
| Current role of endoscopic cholangioscopy |
4 |
| Indications of cholecystectomy in gallstone disease |
4 |
| Predictors of clinical outcomes in cirrhosis patients |
3 |
